$9.41
4.54% yesterday
Nasdaq, Jun 30, 10:00 pm CET
ISIN
US00654J1079
Symbol
ADXN
Sector
Industry

Addex Therapeutics Ltd - ADR Target price 2025 - Analyst rating & recommendation

Addex Therapeutics Ltd - ADR Classifications & Recommendation:

Hold
20%
Sell
80%

Addex Therapeutics Ltd - ADR Price Target

Target Price $0.21
Price $9.41
Deviation
Number of Estimates 3
3 Analysts have issued a price target Addex Therapeutics Ltd - ADR 2026 . The average Addex Therapeutics Ltd - ADR target price is $0.21. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 10 analysts: 0 Analysts recommend Addex Therapeutics Ltd - ADR to buy, 2 to hold and 8 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Addex Therapeutics Ltd - ADR stock has an average upside potential 2026 of . Most analysts recommend the Addex Therapeutics Ltd - ADR stock at Sale.

Sales and Margin forecast 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Revenue Million $ 0.52 0.96
74.51% 85.50%
EBITDA Margin -667.31% -444.00%
386.18% 33.46%
Net Margin 1,711.54% -786.80%
362.32% 145.97%

4 Analysts have issued a sales forecast Addex Therapeutics Ltd - ADR 2025 . The average Addex Therapeutics Ltd - ADR sales estimate is

$965k
Unlock
. This is
19.09% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$2.0m 145.16%
Unlock
, the lowest is
$0.0 100.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $520k 74.51%
2025
$965k 85.50%
Unlock
2026
$965k 0.00%
Unlock
2027
$0.0 100.00%
Unlock

4 Analysts have issued an Addex Therapeutics Ltd - ADR EBITDA forecast 2025. The average Addex Therapeutics Ltd - ADR EBITDA estimate is

$-4.3m
Unlock
. This is
71.30% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-4.2m 67.34%
Unlock
, the lowest is
$-4.3m 72.99%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-3.5m 23.93%
2025
$-4.3m 23.42%
Unlock
2026
$-3.7m 14.11%
Unlock
2027
$-4.0m 8.39%
Unlock

EBITDA Margin

2024 -667.31% 386.18%
2025
-444.00% 33.46%
Unlock
2026
-381.33% 14.11%
Unlock

4 Addex Therapeutics Ltd - ADR Analysts have issued a net profit forecast 2025. The average Addex Therapeutics Ltd - ADR net profit estimate is

$-7.6m
Unlock
. This is
166.40% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-6.5m 156.96%
Unlock
, the lowest is
$-8.5m 174.45%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $8.9m 166.87%
2025
$-7.6m 185.28%
Unlock
2026
$-5.1m 33.33%
Unlock

Net Margin

2024 1,711.54% 362.32%
2025
-786.80% 145.97%
Unlock
2026
-524.53% 33.33%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ 0.09 -0.08
150.00% 188.89%
P/E negative
EV/Sales 10.77

4 Analysts have issued a Addex Therapeutics Ltd - ADR forecast for earnings per share. The average Addex Therapeutics Ltd - ADR EPS is

$-0.08
Unlock
. This is
172.73% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-0.07 163.64%
Unlock
, the lowest is
$-0.09 181.82%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $0.09 150.00%
2025
$-0.08 188.89%
Unlock
2026
$-0.05 37.50%
Unlock

P/E ratio

Current 85.55 235.29%
2025
-121.95 242.56%
Unlock
2026
-182.92 50.00%
Unlock

Based on analysts' sales estimates for 2025, the Addex Therapeutics Ltd - ADR stock is valued at an EV/Sales of

10.77
Unlock
and an P/S ratio of
14.41
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 12.83 112.07%
2025
10.77 16.04%
Unlock
2026
10.77 0.00%
Unlock

P/S ratio

Current 17.16 138.25%
2025
14.41 16.02%
Unlock
2026
14.41 0.00%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today